At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 34 enrolled
Drug / intervention
LY3502970drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Multiple Dose Study to Investigate the Pharmacokinetics, Safety, and Tolerability of LY3502970 in Fed and Fasted Healthy Participants
In Brief
A Phase 1 clinical trial evaluating LY3502970 for Healthy. Completed, enrolled 34 participants across 1 site.
Detailed Summary
The main purpose of this study is to conduct blood tests to measure how much LY3502970 is in the bloodstream and how the body handles and eliminates LY3502970 in healthy participants in fed and fasted states. The study will also evaluate the safety and tolerability of LY3502970 in these participants. The study will last up to 49 days excluding the screening period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesSingapore
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
Enrollment StartNov 2021
First PostedNov 2021
Primary CompletionFeb 2022
TodayJul 2026
First PostedNov 8, 2021
Enrollment StartNov 5, 2021
Primary CompletionFeb 10, 2022
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 4.6 years ago
Interventions
LY3502970drug
Administered Orally.